Literature DB >> 29703542

Prolonged Partial Response to Osimertinib after Disease Progression to Rociletinib in Metastasic EGFR T790M-Positive Non-Small Cell Lung Cancer.

Clara Martínez Vila1, Yolanda Garcia Garcia2, Enric Carcereny Costa2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29703542     DOI： 10.1016/j.jtho.2017.12.015

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  2 in total

1.  Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis.

Authors:  Lei Huang; Hao Huang; Xiao-Ping Zhou; Jin-Feng Liu; Chun-Rong Li; Min Fang; Jun-Rong Wu
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

Review 2.  Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer.

Authors:  Chennianci Zhu; Weihao Zhuang; Limin Chen; Wenyu Yang; Wen-Bin Ou
Journal:  Transl Lung Cancer Res       Date:  2020-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.